Overview

Metformin Plus Irinotecan for Refractory Colorectal Cancer

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.
Phase:
Phase 2
Details
Lead Sponsor:
Barretos Cancer Hospital
Collaborators:
AC Camargo Cancer Center
University of Campinas, Brazil
Treatments:
Camptothecin
Irinotecan
Metformin